FDA Approves Vectibix for Colorectal Cancer
Vectibix, a drug meant for treating patients with advanced colorectal cancer has been approved for use in cases where the cancer has spread to other parts of the body.//Panitumamab, which is being marketed as Vectibix
by Amgen Inc has been found to shrink tumor size and retard cancer cell growth. ...
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
...rnational demand as a result of recent launches of vectibix
Operating Expense Analysis...wer
clinical trial costs for denosumab and vectibix
studies, partially offset b...tor receptor (EGFr) class of antibodies, including vectibix
by the U.S. Food and Drug Administration (FDA). Th...
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
...ncer trials have not shown a treatment benefit for vectibix
in patients whose tumors had KRAS mutations in codon 12 or 13. Use of vectibix
is not recommended for the treatment of colorectal... monotherapy with an EGFr-inhibiting antibody (the vectibix
"With this label update, ph...
Amgen Highlights Data to Be Presented at ASCO
...ill be presented from the PRECEPT trial evaluating vectibix
in combination with FOLFIRI. Consistent with evide...ients with KRAS mutated tumors when treated with vectibix
in combination with FOLFIRI. This may be due to ...apy for a common, severe skin rash associated with vectibix
treatment, will be included in the June 1st ASCO P...
Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
...stin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) despite their high cost. Growth of these agents and the launch of Amgen's vectibix
(panitumumab) will ensure that sales of targeted agents rise from $3.1 million in 2008 to $13.5 million in 2013.
"The increased use of targeted a...
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
...n pipeline products including denosumab in certain oncology indications and vectibix
in colorectal cancer," concluded Sharer.
Product Sales Performance ...uarter was driven by international demand as a result of recent launches of vectibix
in Europe, partially offset by lower U.S. demand.
Operating Expense A...
Targeted Treatments Show Mettle Against Advanced Cancers
...tions in patients with advanced colorectal cancer could indicate that the tumor will not respond to two monoclonal antibodies, Erbitux (cetuximab) and vectibix
Two studies also to be presented at the meeting focused on the brain tumors known as glioblastomas.
One from researchers at the U...
Tests Could Predict Benefit From Cancer Drugs
...715 patients. They confirmed that the cancer drug vectibix
(panitumumab) was only successful in treating adva...orm of the KRAS gene -- not a mutated version.
blocks the epidermal growth factor receptor (EGFR)... on cancer cells.
The patient response rate to vectibix
was 14 percent if they carried the normal KRAS gen...
Caris Diagnostics Providing KRAS Mutational Analysis for Colon Cancer Patients
... has also
published a study noting that their drug vectibix
only works in patients
with wild type KRAS. In Europe, vectibix
is only approved for patients who
have wild type K...nts
when considering treatment with Erbitux and/or vectibix
can order mutation
analysis for KRAS by contacting...
Double binding sites on tumor target may provide future combination therapy
...the clinic or are in late stages of development. For example, Herceptin is an established treatment for certain types of breast cancer and Erbitux and vectibix
are in use for other types of cancer. An additional drug called matuzumab is in phase II clinical trials.
Three years ago, Kate Ferguson, PhD, Assi...
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix
DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, presented at the annual meeting of the American Association for
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic
Colorectal Cancer Patients Published
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Amgen
(NASDAQ:AMGN), today announced final results from a pivotal Phase 3
trial which showed that Vectibix(TM) (panitumumab), a fully human
monoclonal antibody directed against the epidermal growth factor
receptor (EGFr), prolonged progression-...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... mutations, PFS was significantly inferior in the vectibix
arm. These data confirm previous findings when oxa... KRAS mutant tumors were negatively affected when vectibix
was added to a standard chemotherapy regimen. We believe vectibix
should not be used in patients with tumors contain...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...stration's (FDA) decision to put KRAS on the label of two targeted drugs, vectibix
(panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted ...identify nearly all of the patients who will not benefit from taking either vectibix
or Erbitux. These drugs cost tens of thousands of dollars per course of the...